– EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 – CAMBRIDGE, Mass., June 29,…
Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of…
Webull’s investor community can now access real-time BioSig investor communications and Q&AWestport, CT, June 29, 2023 (GLOBE NEWSWIRE) -- BioSig…
Jason Pesterfield, Veteran Med-Tech Executive and Growth Strategist, Named President, and CEO Kirk G. Jacquay, Seasoned Finance & Operations Leader,…
New preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide…
The study was conducted over two days by a team of global key opinion leaders and with participation of executives…
-- Represents the final step before submission of Investigational New Drug (IND) application to FDA, expected in the second half…
Data indicate that GP-2250 has anti-neoplastic effects in virus-negative MCC cells as evidenced by tumor cell viability, proliferation and migrationGP-2250…
– Patient dosing initiated in LUMUS, a 388 patient Phase 2b clinical trial of ESK-001 for the treatment of SLE…
Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese…